½ÃÀ庸°í¼
»óÇ°ÄÚµå
1532135
¼¼°èÀÇ Ç÷°ü Á¢±Ù ±â±â ½ÃÀå Æò°¡ : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°, ±âȸ, ¿¹Ãø(2017-2031³â)Vascular Access Devices Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F |
¼¼°è Ç÷°ü Á¢±Ù ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 36¾ï 3,000¸¸ ´Þ·¯¿¡¼ 2031³â 57¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2024-2031³â CAGR·Î 5.83%ÀÇ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. Áúº´ ºÎ´ã Áõ°¡, ÀÔ¿ø Áõ°¡, ÀÇ·á Á¦µµÀÇ °³¼±¿¡ ÀÇÇØ ½ÃÀåÀº ¿¹Ãø ±â°£¿¡ »ó´çÇÑ ÆäÀ̽º·Î È®´ëÇÒ Àü¸ÁÀÔ´Ï´Ù.
Ç÷°ü Á¢±Ù ±â±â´Â Ç÷°ü¿¡ ¾à¹°, ¾×ü, Ç÷¾× ¹× ¿µ¾ç¼Ò¸¦ Åõ¿©ÇÏ´Â µ¥ »ç¿ëµÇ´Â »ðÀÔ¹°ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â¿¡´Â ¸»ÃÊ »ðÀÔÇü Á᫐ Á¤¸Æ Ä«Å×ÅÍ(PICC), Á᫐ Á¤¸Æ Ä«Å×ÅÍ, ÀÌ½Ä Æ÷Æ®, ¸»ÃÊ Á¤¸Æ Ä«Å×ÅÍ(PIVC) µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÇ·á ¼ºñ½º ¹× ÀÇ·á±â±âÀÇ ²÷ÀÓ¾ø´Â ÁøÈ¿¡ µû¶ó, Ç÷°ü Á¢±Ù ±â±âµµ ¼³°è, Àç·á, À̹Ì¡ ±â¼úÀÇ ÅëÇÕ Ãø¸é¿¡¼ ÁøÈÇØ ¿Ô½À´Ï´Ù. Ç÷°ü Á¢±Ù ±â±âÀÇ ¹ßÀüÀ¸·Î »ýüÀûÇÕ¼º, À¯¿¬¼º, ½ÅÀç·á äÅÃÀÌ Çâ»óµÇ°í ȯÀÚÀÇ °á°ú¿Í »îÀÇ ÁúÀÌ Çâ»óµË´Ï´Ù. Ç÷°ü Á¢±Ù ±â±â¿¡ ´ëÇÑ ¼ö¿äÀÇ Çâ»óÀº »ýÈ°½À°üº´¿¡ ÀÇÇÑ ºÎ´ã Áõ°¡, ±â¼úÀÇ Áøº¸, Àúħ½À ¼ö¼ú¿¡ ´ëÇÑ ¿ä±¸ µî¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷ü °¢ ȸ»ç´Â Áö¼ÓÀûÀ¸·Î ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ°í ÇÕº´ÁõÀ» ÁÙÀ̱â À§ÇØ Àåºñ ¼³°è ¹× Àç·á °³¼±À» À§ÇØ ³ë·ÂÇÏ°í ÀÖ½À´Ï´Ù.
¿¹¸¦ µé¾î Teleflex Incorporated´Â 2024³â 5¿ù Arrow EZ-IO Intraosseous Access Procedure Tray¸¦ Ãâ½ÃÇÏ¿© °ñ³» ¹öŧ·¯ Á¢±Ù Æ÷Æ®Æú¸®¿À¸¦ °ÈÇß½À´Ï´Ù. ¿©±â¿¡´Â °ñ³» Á¢±Ù¿¡ ÇÊ¿äÇÑ ¸ðµç ±¸¼º ¿ä¼Ò°¡ Æ÷ÇԵǾî ÀÖÀ¸¸ç ¹«±Õ ȯ°æ¿¡¼ »ç¿ëÇÒ ¼ö ÀÖ´Â ÃÖÃÊÀÇ FDA ½ÂÀÎ ¹èÅ͸® ±¸µ¿ µå¶óÀ̹ö°¡ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ Æ®·¹ÀÌ´Â ºü¸£°í Á¤È®ÇÏ°Ô »ðÀÔÇÒ ¼ö ÀÖµµ·Ï ¼³°èµÇ¾úÀ¸¸ç, ÀÀ±Þ »óȲ¿¡¼ ¹Ù½ºÅ§·¯ Á¢±Ù¸¦ ¹ÞÀ» ¶§ ÀÓ»óÀÇ°¡ Á÷¸éÇÑ °úÁ¦¸¦ ÇØ°áÇÕ´Ï´Ù. ±×·¯³ª °¨¿°°ú ÆÐÇ÷Áõ°ú °°Àº Ä«Å×ÅÍÀÇ Àå±â »ç¿ë°ú °ü·ÃµÈ À§ÇèÀº ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù.
¸¸¼ºÁúȯ ºÎ´ã Áõ°¡°¡ ½ÃÀå ±Ô¸ð È®´ë
¾Ï, ½ÉÇ÷°ü Áúȯ, ºñ´¢±â Áúȯ µî ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¸¸¼º ÁúȯÀÇ ºÎ´ãÀº ¼¼°èÀûÀ¸·Î Áõ°¡ÇÏ´Â °æÇâÀÌ ÀÖÀ¸¸ç, ÈÇÐ ¿ä¹ý, Åõ¼®, Åõ¾à µîÀÇ Ä¡·á¿¡ ºó¹øÇÏ°í Àå±âÀûÀÎ ¹ö½º Å¥·¯ Á¢±Ù°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ Áß¾Ó Á¤¸Æ Ä«Å×ÅÍ ¹× ¸»ÃÊ Á¤¸Æ Ä«Å×ÅÍ¿Í °°Àº ´Ù¾çÇÑ À¯ÇüÀÇ ¹ö½º Äð·¯ Á¢±Ù ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ºÎ´ã Áõ°¡ÀÇ ¶Ç ´Ù¸¥ ¿äÀÎÀº ÀÌ·¯ÇÑ Áúº´¿¡ °É¸®±â ½¬¿î ³ë³â Àα¸ Áõ°¡ÀÔ´Ï´Ù. ÁøÇà ÁßÀÎ ½Ã³ª¸®¿À·Î ÀÎÇØ Ç÷°ü Á¢±Ù ±â±â¿¡ ´ëÇÑ ¼ö¿ä°¡ ¾ÕÀ¸·Î ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹¸¦ µé¾î, National Institute of Health(NIH)´Â 50¼¼ ÀÌ»óÀÇ ¼ºÀÎÀÌ Àû¾îµµ ÇϳªÀÇ ¸¸¼º ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ±× ¼ö´Â 2020³â 7,152¸¸ 2,000¸í¿¡¼ 2050³â 1¾ï 4,266¸¸¸íÀ¸·Î 99.5% Áõ°¡ÇÒ °æ¿ì¸¦ ¿¹ÃøÇß½À´Ï´Ù. Àü ¼¼°è »ç¸ÁÀÚÀÇ 47%¿¡ ÇØ´çÇÏ´Â ÃßÁ¤ 4,800¸¸ ¸íÀÌ 2060³â±îÁö ½É°¢ÇÑ °Ç° °ü·Ã °íÅëÀ¸·Î »ç¸ÁÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2016³â 2,600¸¸ ¸í¿¡¼ 87% Áõ°¡ÇÕ´Ï´Ù. ÀÌ Áß 83%´Â ÁßÀú¼Òµæ ±¹°¡¿¡¼ ÀϾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ãß°è¿¡ µû¸£¸é 2050³â±îÁö Áö±¸»óÀÇ 60¼¼ ÀÌ»óÀÇ Àα¸´Â 2¹è°¡ µÇ¾î 21¾ï¸íÀÌ µË´Ï´Ù.
½ÃÀå ¼ö¿ä¸¦ ÃËÁøÇÏ´Â ¼³°è °³¼±
Ç÷°ü Á¢±Ù ±â±â´Â Áß¾Ó Á¤¸Æ Ä«Å×ÅÍ(CVC), ÀÚ°¡ Ç÷°ü µ¿Á¤¸Æ ´©°ü(AVF), Àΰø Ç÷°ü µ¿Á¤¸Æ À̽Ä(AVG) µîÀÌ ÀÖ½À´Ï´Ù. CVCÀÇ Ã·´Ü ¹× ÄÚÆà ¼³°èÀÇ Çõ½ÅÀº °³Á¸¼º°ú Ç÷·ù ¼Óµµ¸¦ °³¼±Çß½À´Ï´Ù. AVF´Â CVC¿¡ ºñÇØ, ÀÀ°í³ª °¨¿°À» ÀÏÀ¸Å°±â ¾î·Æ°í, ½Å·Ú¼ºÀÌ ³ô°í ÃæºÐÇÑ Ç÷·ù·®À» È®º¸ÇÒ ¼ö Àֱ⠶§¹®¿¡ ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼³°è °³¼±À¸·Î AVF Çü¼º ±â±â´Â ½ÃÀå ¼ºÀåÀ¸·Î À̾îÁö´Â Å« ±â¼¼¸¦ °¡Áö°í ÀÖ½À´Ï´Ù. ½ÃÀå ±â¾÷Àº ¼³°è¸¦ °ÈÇÑ Çõ½ÅÀûÀÎ Á¦Ç°À» Ãâ½ÃÇÒ ±âȸ¸¦ ³ë¸®°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 9¿ù, Laminate Medical Technologies´Â Åõ¼® Á¢±Ù¸¦ À§ÇÑ AVF Çü¼º ±â±âÀÎ VasQ External Vascular SupportÀÇ ¹Ì±¹ FDA ÀÎÁõÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÁÖ¸ñÇÒ Á¡Àº VasQ¸¦ »ç¿ëÇÑ ÀÓ»ó½ÃÇè¿¡¼ ȯÀÚÀÇ 80%°¡ Ä¡·á ½ÃÀÛ ÈÄ 1³â À̳»¿¡ Á᫐ Á¤¸Æ Ä«Å×Å͸¦ Á¦°ÅÇÒ ¼ö ÀÖ¾î ÀüÅëÀûÀÎ AVF¿¡ ºñÇØ °¨¿° À§ÇèÀÌ °¨¼ÒÇÑ °ÍÀÔ´Ï´Ù. VasQ´Â AVF Çü¼º µ¿¾È Ç÷°üÀ» ±¸Á¶ÀûÀ¸·Î º¸°ÇÏ¿© ´õ ³ªÀº µ¿¸Æ È帧°ú ±â´É¼ºÀ» ÃËÁøÇÕ´Ï´Ù.
º» º¸°í¼´Â ¼¼°èÀÇ Ç÷°ü Á¢±Ù ±â±â ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇÏ¿© ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø, ½ÃÀå ¿ªÇÐ, ÁÖ¿ä ±â¾÷ÀÇ Á¤¼¼¿Í Àü¸Á µîÀÇ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù.
Global vascular access devices market is projected to witness a CAGR of 5.83% during the forecast period 2024-2031, growing from USD 3.63 billion in 2023 to USD 5.71 billion in 2031. With increasing disease burden, rising hospitalization, and an improved healthcare system, the market of vascular access devices is anticipated to expand at a notable pace during the forecast period.
Vascular access devices are insertions used to administer drugs, fluids, blood, and nutrients in blood vessels. These devices include peripherally inserted central catheters (PICCs), central venous catheters, implantable ports, and peripheral intravenous catheters (PIVCs). With the never-ending evolution of healthcare services and medical devices, vascular access devices have evolved in terms of design, material, and integration of imaging technologies in it. Advancements in vascular access devices have improved biocompatibility, flexibility, and the adoption of novel materials, enhancing patient outcomes and quality of life. The rising demand for vascular access devices is driven by the growing burden of lifestyle diseases, technological advancements, and the need for minimally invasive procedures. Manufacturers are consistently working to enhance device design and materials to improve patient outcomes and reduce complications.
For instance, in May 2024, Teleflex Incorporated launched the Arrow EZ-IO Intraosseous Access Procedure Tray, enhancing its intraosseous vascular access portfolio. It includes all necessary components for intraosseous access, featuring the first FDA-cleared battery-powered driver that can be utilized in sterile environments. The tray is designed for quick and precise insertion, addressing the challenges clinicians face in obtaining vascular access during emergencies. However, risks associated with long-term use of catheters, such as infections and sepsis may pose challenges for market growth.
Rising Burden of Chronic Diseases to Increase the Market Size
The chronic disease burden is on a rise globally, owing to the increasing prevalence of chronic diseases, such as cancer, cardiovascular and urological disorders, and others, which necessitates frequent and long-term vascular access for treatments such as chemotherapy, dialysis, and medication administration, thereby driving the demand for various types of vascular access devices, including central venous catheters and peripheral IV catheters. Another factor contributing to the growing burden is the rising geriatric population, highly prone to catching such diseases. With the ongoing scenario, the future demand for vascular access devices is anticipated to increase further.
For instance, the National Institute of Health (NIH), anticipates that the number of adults 50 years and older suffer from at least one chronic disease, which will increase by 99.5% from 71.522 million in 2020 to 142.66 million in 2050. An estimated 48 million people, or 47% of all deaths globally, are expected to die from severe health-related suffering by 2060, an 87% increase from 26 million in 2016. It is anticipated that 83% of these deaths will occur in low and middle-income countries. As per World Health Organization (WHO) estimates, by 2050, there will be twice as many people 60 years or older on the planet with the population of 2.1 billion.
Design Improvements to Drive Market Demand
The established types of vascular access devices include central venous catheters (CVCs), arteriovenous fistulas (AVFs), and arteriovenous grafts (AVGs). Innovations in CVC tip and coating design have improved patency and blood flow rates. AVFs are preferred over CVCs as they are less prone to clotting and infection while providing reliable and adequate blood flow rates. With such design enhancements, the AVF creation devices have significant traction leading to market growth. Market players are taking chances to launch innovative products with enhanced designs. For instance, in September 2023, Laminate Medical Technologies announced that it received US-FDA clearance for its VasQ External Vascular Support device, designed to create AVFs for dialysis access. Notably, 80% of patients in trials using VasQ were able to remove central venous catheters within their first year of treatment, reducing the risk of infection compared to traditional AVFs. The VasQ device provides structural reinforcement to the vessels during AVF creation, promoting better arterial flow and functionality.
Drug Administration Application to Dominate Vascular Access Devices Market Share
The drug administration application of the vascular access devices market is anticipated to cover the highest market share. As these devices provide reliable, long-term access to the bloodstream, which is essential for patients needing frequent or prolonged intravenous therapies, such as chemotherapy or chronic disease management, reducing complications associated with traditional IV lines, such as infections and vein irritation, by minimizing the need for repeated needle sticks. A recent study published in the British Medical Journal in July 2024 examined the effectiveness of vascular access devices (VADs) in reducing infection rates among hospitalized patients. The study concluded that VADs along with specific safety measures reduce the chances of infection.
North America Dominates the Global Vascular Access Devices Market Share
North America is anticipated to hold major market share of the global vascular access devices market. North America's leadership in the demand for vascular access devices is attributed to its advanced healthcare infrastructure, rising prevalence of chronic diseases, technological innovations, supportive regulations, and demographic trends favoring increased healthcare needs. According to the United States Renal Data System 2023 Annual Data Report, published in April 2024, more than 85% of individuals who began hemodialysis used a catheter. Additionally, nearly three-quarters of the United States population started without permanent access, a significant increase from about 65% in 2018. This rise in number clearly shows an increasing consumption of such devices in North America causing it to hold the largest market share among other regions.
Future Market Scenario (2024 - 2031F)
The vascular access devices market has witnessed several remarkable futuristic advancements that are anticipated to shape the future of such devices. These advancements include wearable technology, remote monitoring of atrioventricular flow, use of biocompatible materials for product design, 3D printing technology, image-guided vascular access devices, and others. The USFDA approval of WavelinQ and Ellipsys, two vascular access devices that facilitate the creation of arteriovenous fistulas (AVFs) using minimally invasive techniques has paved a new path for more products in line with endovascular fistula creation. The of the most revolutionary advancement is the image-guided vascular access system, Ultreon 1.0 launched by Abbott in October 2023. This platform uses near-infrared light to provide high-definition, precise imaging from within the blood vessels, allowing the healthcare professional precise access to blood vessels even in the most complex anatomies.
Key Players Landscape and Outlook
The market witnessed some substantial market deals such as acquisitions, regulatory approvals, and product launches to expand the share of key players in the global vascular access devices market. In June 2023, Merit Medical announced two strategic acquisitions totaling USD 132.5 million to enhance its dialysis catheter portfolio. Merit Medical is acquiring dialysis catheters and a sealant system from AngioDynamics for USD 100 million, which complements its biopsy devices by preventing pneumothorax during lung biopsies. Additionally, Merit is purchasing the Surfacer catheter system from Bluegrass Vascular Technologies for USD 32.5 million, which facilitates central venous access.
In November 2023, BD launched the SiteRite 9 Ultrasound System, which is an advanced vascular access ultrasound designed to enhance clinician efficiency in placing peripherally inserted central catheters (PICCs), central venous catheters, and IV lines. SiteRite 9 aims to increase first-attempt insertion success and reduce unnecessary needlesticks, supporting BD's vision of a One-Stick Hospital Stay. The system received 510(k) Clearances in September 2023 and is available in the United States
market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.